FDA issues complete response letter to Sobi’s NASP for gout

Sobi intends to request a meeting with the FDA to discuss the feedback, consider the necessary steps for resubmission and work closely with CMOs to address the outlined deficiencies. Credit: Tapati Rinchumrus/Shutterstock.com.